Genprex Partners with CDMO to Scale Diabetes Gene Therapy Manufacturing — Genprex, Inc.

Event summary

Genprex has entered a manufacturing agreement with a leading U.S. CDMO to scale up its diabetes gene therapy program.
The partnership transitions production from academic research to cGMP-compliant clinical and commercial manufacturing.
Key priorities include process optimization, scale-up using bioreactors, and analytical qualification for potency and purity.
Genprex's therapy aims to treat both Type 1 and Type 2 diabetes by delivering Pdx1 and MafA genes via AAV vector.
Preclinical studies show promising results in restoring normal blood glucose levels and improving insulin production.

The big picture

Genprex's strategic partnership with a CDMO marks a critical step in transitioning its diabetes gene therapy from research to clinical-stage manufacturing. This move aligns with broader industry trends toward outsourcing complex biologic production to specialized CDMOs, ensuring scalability and regulatory compliance. The collaboration is pivotal for Genprex's goal of developing life-changing therapies for diabetes, a market with significant unmet needs.

What we're watching

Manufacturing Execution: How the CDMO partnership will impact the timeline and success of Genprex's IND-enabling preclinical studies and future clinical trials.
Regulatory Pathway: Whether the rigorous quality control protocols and cGMP compliance will facilitate smoother regulatory submissions.
Therapeutic Potential: The pace at which Genprex can advance its diabetes gene therapy program toward clinical evaluation, focusing on safety and efficacy.